［10］Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants［J］. J Pediatr, 2003, 143 (5 Suppl): S150-S156.
［1］The IMpact RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high risk infants［J］. Pediatrics, 1998, 102(3 Part 1): 531-537.
［11］Wang EE, Law BJ, Stephens E, Pediatric Investigators Collaborative Network in Canada (PICNIC) Prospective study of Risk Factors and outcomes in Patients Hospitalized with Respiratory Syncytial Viral Lower Respiratory Tract Infections［J］. J Pediatr, 1995, 126(2):212-219.
［2］Langley JM, LeBlanc JC, Smith B, Wang EE. Use of palivizumab in children with congenital heart disease［J］. Pediatr Child Health, 2003, 8(10): 632-633.
［3］Law BJ, Langley JM, Allen U, Paes B, Lee DS, Mitchell I, et al. The Pediatric Investigators Collaborative Network in Canada (PICNIC) Study of predictors of hospitalisation for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation［J］. Pediatr Infect Dis J, 2004, 23(9): 806-814.
［12］Law B, MacDonald N, Langley J, Mitchell I, Stephens D, Wang E, et al. Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: What are we trying to prevent? ［J］. Paediatr Child Health, 1998, 3(6): 402-404.
［13］Canadian Pediatric Society Statement. Palivizumab and respiratory syncytial virus iImmuneglobulin intravenous for the prophylaxis of respiratory syncytial virus infection in high-risk infants［J］. Pediatr Child Health, 1999, 4: 474-480. February 2005 Update.
［14］American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Policy statement: revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections［J］. Pediatrics, 2003, 112: 1442-144. February 15, 2004 Update.
［4］Joffe S, Escobar GJ, Black SB, Armstrong MA, Lieu TA. Rehospitalization for respiratory syncytial virus among premature infants［J］. Pediatrics, 1999, 104(4 Pt 1): 894-899.
［5］Boyce TG, Mellen BG, Mitchel EF, Jr., Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid［J］. J Pediatr, 2000, 137(6): 865-870.
［15］Macagno I. Recommendations of the Italian Society of Neonatalogy for the prevention of respiratory syncytial virus (RSV) diseases［J］. Pediatr Med Chir, 2005, 27(3-4): 78-87.
［6］Liese JG, Grill E, Fischer B, RoecklWiedmann I, Carr D, Belohradsky BH. Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany［J］. Eur J Pediatr, 2003, 162(4): 230-236.
［7］Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group［J］. Pediatrics, 1997, 99(1): 93-99.
［8］Meissner C. Commentary: The unresolved issue of risk factors for hospitalization of infants with respiratory syncytial virus infection born after 3335 weeks gestation［J］. Pediatr Infect Dis J, 2004, 23: 821-823.
［9］Horn SD, Smout RJ. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes［J］. J Pediatr, 2003, 143 (5 Suppl): S133-S141.
［10］Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants［J］. J Pediatr, 2003, 143 (5 Suppl): S150-S156.
［11］Wang EE, Law BJ, Stephens E, Pediatric Investigators Collaborative Network in Canada (PICNIC) Prospective study of Risk Factors and outcomes in Patients Hospitalized with Respiratory Syncytial Viral Lower Respiratory Tract Infections［J］. J Pediatr, 1995, 126(2):212-219.
［16］Azar P, Broglia B, Micelli INP, et al. Guidelines for the use of palivizumab in the prevention of RSV disease: a consensus opinion［J］. Pediatrics in Review (Spanish), 2000, 21(2): 62-68.
［12］Law B, MacDonald N, Langley J, Mitchell I, Stephens D, Wang E, et al. Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: What are we trying to prevent? ［J］. Paediatr Child Health, 1998, 3(6): 402-404.
［13］Canadian Pediatric Society Statement. Palivizumab and respiratory syncytial virus iImmuneglobulin intravenous for the prophylaxis of respiratory syncytial virus infection in high-risk infants［J］. Pediatr Child Health, 1999, 4: 474-480. February 2005 Update.
［14］American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Policy statement: revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections［J］. Pediatrics, 2003, 112: 1442-144. February 15, 2004 Update.
［15］Macagno I. Recommendations of the Italian Society of Neonatalogy for the prevention of respiratory syncytial virus (RSV) diseases［J］. Pediatr Med Chir, 2005, 27(3-4): 78-87.
［17］Figueras-Aloy J, Carbonell-Estrany X, Quero J IRIS Study Group. Case-Control Study of the Risk Factor Linked to Respiratory Syncytial Virus Infection Requiring Hospitalization in Premature Infants Born at a Gestational Age of 33 to 35 Weeks in Spain［J］. Pediatr Dis J, 2004, 23(9):815-820.
［16］Azar P, Broglia B, Micelli INP, et al. Guidelines for the use of palivizumab in the prevention of RSV disease: a consensus opinion［J］. Pediatrics in Review (Spanish), 2000, 21(2): 62-68.
［18］Sampalis JS, Langley J, Carbonell-Estrany X, Paes B, O′Brien K, Allen U, et al. Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation medical decision making June 12 2008:doi10.1177/0272989x08315238.
［17］Figueras-Aloy J, Carbonell-Estrany X, Quero J IRIS Study Group. Case-Control Study of the Risk Factor Linked to Respiratory Syncytial Virus Infection Requiring Hospitalization in Premature Infants Born at a Gestational Age of 33 to 35 Weeks in Spain［J］. Pediatr Dis J, 2004, 23(9):815-820.
［18］Sampalis JS, Langley J, Carbonell-Estrany X, Paes B, O′Brien K, Allen U, et al. Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation medical decision making June 12 2008:doi10.1177/0272989x08315238.
